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Every day, the body is threatened by many pathogens which differ greatly in appearance, route of entry etc. In order to protect from this wide range of threats, the immune system has many different branches cooperating in one complex system. A first important distinction that can be made is between the innate and adaptive immune system. The adaptive part recognizes pathogens by certain patterns that are conserved between species of pathogens and are crucial for its function. Exactly what patterns an individual’s immune system will recognize are largely genetically determined and are stable during its lifetime. The adaptive or specific immunity is the other side of the coin: it does not recognize patterns, but highly specific epitopes. Also, it is not (entirely) genetically determined and can learn to cope with new pathogens. 

The Th1/Th2 paradigm
Adaptive immunity in turn has traditionally been split in T helper (Th) 1 and Th2 responses, two different subtypes of CD4+ T helper cells1. Th1 mediates defence against intracellular pathogens like viruses and parasites, while Th2 is associated with protection against extracellular pathogens1. Differentiation to Th1 eventually leads to cytotoxic T cell (CTL) activity and Th2 differentiation leads to a humoral immune response involving antibody producing B cells, mast cells and eosinophils. 
Both Th cell types arise from a common precursor, the naïve Th cell. The decision to mature into one or the other type depends on cytokine signals present in the environment inducing gene expression. Presence of interleukin (IL) -12 skews differentiation into Th1 and IL-4 on the other hand results in Th2 cells. Cytokines secreted by one type of cell inhibits differentiation of precursors in the other cell subset2. Interferon-gamma (IFN-γ) for instance is produced by the Th1 subset and down-regulates proliferation of Th2 cells. In turn, Th2 cytokines IL-4 and IL-10 can block IL-12 production, thereby reducing differentiation into Th12. This cross-regulation results in a balance between the two subsets with their differential effector mechanisms. Distortion of this balance has been implicated to lie at the basis of diseases like allergy asthma and autoimmunity3.

New kids on the block
Although the existence of T-cell subtypes gave more insight in the mechanisms underlying immunity, it could not explain the body’s unresponsiveness to non-pathogenic antigens like intestinal bacteria. These phenomena turned out to be mediated by so-called regulatory T cells (Tregs), cells suppressing immune responses4. Tregs are important in the immune system, but lie beyond the scope of this paper and will not be discussed thoroughly.
Besides Tregs, another new Th subtype has been identified, called Th17 for its IL-17 secretory capabilities5. After its discovery, it was soon implied to be involved in many immune disorders and will therefore be subject of this thesis. 
The discovery of these new T cell subtypes clearly indicate that the immune system is more complex than proposed in the Th1/Th2 paradigm. Similar as in the Th1/Th2 paradigm, it is proposed that different Th subtypes are involved in different immune diseases. Therefore, understanding of how this balance is regulated is important to understand the mechanisms underlying these diseases. 





In 1989 Mossman and Cofman6 first proposed the Th1/Th2 paradigm, in which Th1 cells assist in eradicating viruses and other intracellular pathogens, and Th2 cells are important in humoral immunity and control of parasite infections7. However, this paradigm could not fully explain pathological exacerbations of the immune system. Attempts to understand this led to the discovery of a new Th subset, called Th17 after its first discovered cytokine

Murine Th17 development
As stated above, Th1 and Th2 cells depend on their effector cytokines for differentiation from naive T cells8. These same cytokines (interferon (INF)-γ and IL-4 respectively) block Th17 development. In mice, Th17 cells are shown to depend on TGF-β and IL-6 for differentiation 9. IL-6 is a proinflammatory cytokine produced in large amounts by innate immune cells upon activation of pattern recognition receptors8. In contrast, transforming growth factor (TGF)-β is regarded as an anti-inflammatory cytokine since loss of the cytokine leads to deadly immune overactivation10 and was already known to be required for differentiation of naive T cells into Tregs. Therefore, IL-6 prevents generation of Tregs in favour of Th17 cells9. Upon stimulation with these cytokines, naive T cells upregulate retinoic acid-related orphan receptor (ROR)γt and, as more recently discovered, RORα in a signal transducer and activation of transcription (STAT) 3-dependent way. RORγt in turn, acts as a master regulator driving differentiation to the Th17 phenotype (Fig 1)11-13. 
Also involved in Th17 generation is IL-21, this cytokine produced by natural killer (NK) and Th17 cells is described to drive differentiation of naive T cells into Th17, although not as strong as IL-614. IL-21-/- mice Th17 cells are still generated, indicating that the cytokine is not essential for Th17 development14. However, Th17 cell numbers in these mice are significantly reduced, indicating that the cytokine does play a role in development8. During differentiation it is produced in large amounts by newly formed Th17 cells and acts as a positive feedback loop driving other naive cells to differentiate into Th17 as well (fig 1.8)8, 14. After differentiation of the Th17 cell, another cytokine, IL-23, comes into play. Its presence is required by IL-6 and TGF-β stimulated cells (like Th17 cells) in order to be able to induce tissue inflammation and it downregulates expression of IL-1015. This led to the suggestion that IL-23 stabilizes the phenotype of newly formed Th17 cells8. IL-10 is one of the cytokines produced by Tregs, but not by Th17 cells16, which might indicate that the cells used for this experiment were not fully developed into Th17 cells, despite IL-6 stimulation. This close affiliation of Tregs and Th17 cells starts early in differentiation; both cell types require TGF-β, but presence of IL-6 or IL-21 determines whether a naive cell will be proinflammatory (Th17) or immunosuppressive (Treg). Even after being fully differentiated, murine Tregs can be reprogrammed into Th17 cells by DCs activated with an antibody crosslinking B7-DC (B7-DC Xab)17 or by adding a mixture of Th17 inducing cytokines (IL-1, IL-21 and most potently: IL-6)11. IL-6 was also shown to downregulate FOXP3 expression11. This important Treg transcription factor in turn, can bind to RORγt, preventing Th17 differentiation.
Taken together, these findings implicate that (in mice) generation of Tregs and Th17 cells is related and depends on presence of IL-6. As inducers of both cell types inhibit differentiation into the other subset, this could result in a balance between Tregs and Th17 cells, similar as described for Th1/Th2 helper cells. 

Human Th17 development
The origin and differentiation signals of human Th17 cells are very different from those in murine cells. First TGF-β, of undeniable importance for murine Th17 development, shows contradicting effects. Several studies show Th17 development independent of TGF-β, but this might be due to bovine cytokine present in the culture medium used in these experiments18. Others indicate TGF-β to be indispensable for Th17 generation19-21. One of these19 shows that TGF-β upregulates RORγt, but simultaneously inhibits its ability to upregulate IL-17 expression. A second paper shows TGF-β, IL-6, IL-21 and IL-1β all to be required, but to have differential effects, dependent on the relative concentrations of the cytokines20. More important, lack of TGF-β induced a Th1-like profile in this experiment. The third article21 states that both IL-21 and TGF-β are indispensable for differentiation and induce RORγt expression.
To complicate this model even further, a recent article shows Th17 cells to originate exclusively from a certain subset of CD4+ naive Tcells expressing CD161, a transmembrane protein with an up-to-day unknown function22. These cells did not depend on TGF-β for RORγt expression, but expressed it constitutively, in contrast to the CD161- cells which did not express it at all and were restricted to Th1 or Th2 commitment. In the CD161+ cells expression of both RORγt and Tbet (a transcription factor critical for Th1 development) was enhanced upon stimulation with IL-23 and IL-1β, but not by IL-6. Addition of TGF-β did enhance RORγt expression and decreased Tbet, but was not indispensable. Furthermore, the proportion of IFN-γ producing (Th1-like) cells decreased. In turn, IL-4 or IL-12 diminished RORγt expression in favour of Tbet (Th1) or GATA3 (Th2) respectively18. Taken together, this could implicate that although TGF-β is not a critical factor for Th17 development. Instead, it decreases skewing towards a Th1 phenotype in favour of Th17 (Fig 2). Another aspect in Th17 development supporting this theory is the existence of Th cells expressing both IFN-γ and IL-17, so-called Th17/Th1 cells23. It suggests even more flexibility between the two subsets, with variations in TGF-β concentrations determining whether Th1, Th17 or Th17/Th1 cells arise.





Th17 effector functions in healthy individuals

Th17cells target specific pathogens
Just like Th1 and Th2 cells, Th17 cells are believed to be required for clearance of a certain type of pathogens. Several different classes of pathogens are shown to initiate a Th17 response; Gram-positive, Gram negative and acid-fast bacteria , fungi and even the parasite  toxoplasmosis gondii24-29. A major role of Th17 appears to be attracting other immune cells, being neutrophils, monocytes, CD4+ memory T cells and B-cells30. Knockouts of the IL-17 cytokine or receptor, as well as mice treated with blocking antibodies, show a defective granulocyte response and enhanced susceptibility to infection with K. pneumoniae24, 31. In these mice lung epithelial tissue shows decreased production of CXC chemoattractants, stemm cell factor (SCF) and Granulocyte-Colony Stimulating Factor (G-CSF) in response to infection32(Fig 3). Besides attracting neutrophils, IL-17 has been shown to indirectly attract Th1 effector cells to M. tuberculosis granulomas by regulation of CXCR3 ligands MIG, IP-10 and I-TAC27. In this experiment, however, IL-17 was not required for the primary control of M. tuberculosis, since no increased susceptibility for infection was seen in knockout mice27. However, other Th17 cytokines might be relevant defence against M. tuberculosis, but were not tested in this experiment. For another intracellular pathogen, Listeria monocytogenes, IL-17 knockouts showed no increased susceptibility either32. This indicates that IL-17 is more important for defence against extracellular pathogens rather than intracellular. Since Th17 cells appear to be suited best for targeting extracellular pathogens, cooperation with Th2 cells appears likely. As mentioned above, however, IL-4 inhibits Th17 development and in turn, TGF-β prevents Th2 differentiation. 
Besides the clear role of IL-17 in host defence, another Th17 derived cytokine, IL-22, is of importance as well. This cytokine is indispensible in fighting off extracellular pathogens32, 33 and will be discussed more thorough below.
As mentioned above, fungal infections are shown to induce a Th17 response28, but the role of Th17 in fungal infections remains a matter of debate. IL-17 has been shown to downregulate Th1 responses towards fungal infection34 in vivo and to inhibit antifungal activity in vitro16. As well, two separate experiments show a lack of IL-1735 or IL-2136 to improve immunopathology caused by fungal infection. Taken together, these findings indicate a role in pathology instead of host defence upon fungal infection. However, neutrophils are indispensable in defence against fungi and IL-17 attracts these cells, a positive role in fighting off fungi cannot be excluded. 
For an adequate antiviral response, Th1 cells are known to be indispensable. Since IL-17 is known to inhibit maturation of other Th subsets, IL-17 induced inhibition of Th1 development could be beneficial for a virus. Indeed, an IL-17 homologue is described in the genome of a herpesvirus and is considered relevant for the virus’ persistence in its host37, 38. As well, a vaccinia virus complemented with the IL-17 gene showed increased replication in vivo, but not in vitro, indicating Th17 responses to be beneficial for evading the immune system instead of increased viral replication per se39. 
Summarizing, Th17 responses probably hamper antiviral immunity and play an unknown role in fighting off fungal infections. On the other hand, Th17 responses beneficial and indispensable in immunity against extracellular bacteria and, in some diseases, cooperate with the Th1 subset in clearing intracellular infections. 

IL-17: a cytokine important for the immune system
IL-17A is the first member of the IL-17 family discovered and has four other family members, designated IL-17B-F16. Though, since IL-17B-D are not produced by Th17 cells and the origin of IL-17E is still unknown, this thesis will focus on the other two family members. IL-17A and IL-17F are found as IL-17A homodimers or IL-17A-F heterodimers. Specifically blocking IL-17A has more effect than blocking IL-17F40. Therefore, we will speak of the combination of homo- and heterodimers as IL-17 in this article.
As described above, IL-17 signalling induces production of CXC chemokines, G-CSF and SCF. The chemokine production can synergize with TNF-α signalling, giving a higher production than induced the sum of both cytokines16.
Besides indirectly attracting immune cells, IL-17 can also contribute to granulopoiesis. IL-17RA knockouts only show a slight decrease in neutrophils counts, but a significantly impaired recovery of neutrophil counts after sublethal irradiation41. Systemic overexpression of IL-17, in turn, leads to massive haematopoiesis caused by the induction of G-CSF and SCF production42.

IL-17 receptor
The first discovered receptor for IL-17 is IL-17RA. It is has a 293 amino acid (aa) extracellular domain, a short transmembrane (23aa) domain and a long intracellular tail consisting of 525aa38. In mice, IL-17RA mRNA is expressed in the lungs, kidneys, spleen and liver as well as in isolated fibroblasts, mesothelial, epithelial and various myeloid cells38. Mice lacking the receptor are unable to bind IL-17 to T or B lymphocytes24. In humans, receptor mRNA is found in epithelial cells, fibroblasts, T and B lymphocytes, marrow stromal cells and myelomonocytic cells16, 43. The protein itself is reported on human T lymphocytes and vascular epithelial cells16. Moreover, IL-17 induced G-CSF and CXCL1 can be blocked completely using neutralizing antibodies for IL-17RA16. However, IL-17RA binds its ligand with relatively low affinity; only one-tenth of what is to be expected based on the effects it induces16, 38. This led to the hypothesis that another receptor would have to be involved for proper IL-17 signalling. One candidate is IL-17RC, another transmembrane receptor. The two (human) receptors are shown to co-immunoprecipitate when expressed in a murine (IL-17-/-) cell line and to bind and respond to IL-17 only when co-expressed in the same cell44. As well, cells from IL-17RC deficient mice fail to generate a response to both IL17 and IL-17F45. Taken together, this could indicate that IL-17RA and IL-17RC heterodimers are required for IL-17 signalling, but experiments were performed on mice or on transfected murine cells, not on human primary cells. Besides, IL-17RC expression is reported in human cartilage, prostate, liver, heart, kidney and muscle cells46, which differs from IL-17RA expression. And of course, if a requirement for IL-17RA/C heterodimers exists, the two receptors will have to be co-expressed in all cells shown to respond to IL-17 stimulation. Summarizing, IL-17RA and C cooperation might explain why IL-17RA alone has such a low affinity for its ligand, but biological relevance in human cells remains to be determined.

IL-22 in defence and epithelial barrier regulation
IL-22 is a cytokine produced by various immune cells. Anti-CD3 stimulated T cells, NK cells and Th1 cells are all described to produce the cytokine, but Th17 cells are by far the dominant IL-22 producers16. Its production is stimulated by IL-6 and IL-2345, both essential for Th17 development. Therefore, it will come to no surprise that IL-17 and IL-22 are normally co-expressed in Th17 cells16. In vivo studies demonstrated that IL-22 is indispensable to fight various extracellular infections, as are Th17 cells in general32, 45. The IL-22 receptor is composed of two chains, the ubiquitously expressed IL-10R2 and the IL-22R chain, which is not expressed on immune cells16. Instead, it is expressed on and elicits responses from many types of epithelial cells16. One of these responses is inducing a proinflammatory response47-49, such as the production of acute-phase proteins, chemokines and other cytokines. A second class of molecules produced upon IL-22 stimulation is a broad variety of antimicrobial peptides like β-defensins and S100-family proteins47-49. A third mode of action does not involve production of cytokines, but a mechanical effect instead. Together with IL-17, IL-22 can disrupt tight junctions in epithelial barriers50, possibly to allow other cells to enter immune-privileged compartments, for example by allowing them to cross the blood-brain barrier. And although not mentioned by the authors, it could explain why Th1 cells can only enter the lungs with Th17 involvement upon M. tuberculosis infection (however, this effect is only described as an IL-17 dependent effect).


Multiple roles for IL-21
As mentioned above, IL-21 can favour development of Th17cells over Tregs and its autocrine loop amplifies Th17 responses and its own expression14. Its receptor shows similarities with the IL-2R, including being associated with the γc-chain51. It is expressed on macrophages, dendritic, epithelial, B, T and NK cells and has a function broader than merely regulating differentiation of the Th17 subtype 16. First its influence on the other T cell subtypes; IL-21 can promote both cellular and humoral responses which are traditionally considered Th1 (IFN-γ) and Th2 (IL-4) mediated. Cellular immunity is augmented in several ways. First, it stimulates IFN-γ production by both Th1 and NK cells 52, 53. In addition, it stimulates in vitro NK cell maturation 54 and once maturated these cells show enhanced proliferation and cytotoxicity upon IL-21 stimulation, while  survival is decreased55. However, IL-21-/- mice show normal NK cell numbers 56, indicating that IL-21is not required for NK development. However, biological functions of IL-21 for human NK cells in vivo will have to be examined more thoroughly.
Other effector cells of cellular immunity are CD8+ T cells, which are augmented by IL-21. Both naive and memory CD8+ T cells are enhanced in proliferation and activation by the cytokine57. On the other hand, IL-21 is also shown to inhibit CD8+ proliferation58. Normally, DCs present antigens to CD8+ cells. When the CD8+ cells’ TCR binds an antigen presented on an MHC molecule, the DC activates it. After short stimulation of DCs with IL-21, they completely lose the capability to induce CD8+ proliferation. Even further, mice injected with these IL-21 stimulated DCs fail to develop T cell mediated contact hypersensitivity (CHS) (while control mice do develop this immunopathology)58. This suggests a protective role for Th17 cells in CHS, but this will be discussed more thoroughly below.




Since Th17 cells and cytokines appear to have a pivotal role in regulating immune responses, it will come to no surprise that these cells play a major role in immunopathology as well. In several autoimmune diseases previously thought to be Th1 mediated, Th17 cells appear to be more pathogenic. IL-17, IL-22 and IL- 23 are all shown to be upregulated in several autoimmune diseases which will be discussed below. As well, Th17 cells are found to infiltrate diseased tissue in patients with rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis, Crohn disease and primary Sjögren’s Syndrome (pSS) 62, 63. In short, activated Th17 cells attract neutrophils to inflamed tissue. Overactivation of these cells leads to tissue damage as seen in many diseases34, but most work performed in the field involves the cytokine patterns regulating the immune response. The following section will describe the role of Th17 cells in several autoimmune diseases and experimental disease models and will focus on these cytokine patterns.

Systemic Lupus Erymathosus (SLE)
SLE is an autoimmune disease with a broad range of clinical manifestations in skin, kidneys, lungs, brain, heart, blood vessels and cells, serosal surfaces and joints59. In several disease models, IL-21 is shown to be a contributing factor. First, BXSB-Yaa mice, a strain spontaneously developing SLE-like symptoms, express high levels of IL-2160. Neutralization of IL-21 early in disease, increased disease severity, whereas late neutralization increased survival64. Implications of these findings are unclear, but could point to different effects of IL-21 stimulation on T and B-cells, inducing increased Th17 activation and B-cell apoptosis respectively59. Second, the sanroque mouse, having a mutation leading to excessive IL-21 expression, develops SLE-like symptoms as well. A third mouse model, MRL-lpr, does not have increased levels of IL-21 upon stimulation with anti-CD3, but a combination of anti-CD3 and anti-CD28 resulted in a 10-fold higher IL-21 expression compared to control65. As well, neutralization of the cytokine led to a reduction of skin lesions, anti-dsDNA antibodies, absolute T cell numbers in the spleen, proteinuria and lymphadenopathy. Since a reduced concentration of autoreactive antibodies was found neutralizing IL-21 must affect both B and T cells65. 
In human SLE, peripheral B cells show a reduced expression of IL-21R, but this might be caused by expansion of altered B cell subsets59. Furthermore, IL-21 concentrations were elevated in SLE-patients, but so were several other Th1 and Th17 cytokines and no correlation between IL-21 levels and disease severity or anti-dsDNA could be shown59. On the other hand, IL-21 polymorphisms are shown to associate with SLE66. In conclusion, the role of IL-21 in SLE remains unclear, but these contradicting reports could be due to IL-21 having different effects in early and late disease, as seen in the BXSB-Yaa mice.

Experimental autoimmune encephalomyelitis (EAE) and MS
EAE is an experimental animal model for human MS. This disease is characterized by autoreactive Th cells causing inflammatory lesions in the central nervous system (CNS)59. Like other autoimmune diseases, EAE was previously thought to be Th1 mediated30. However, mice deficient in IL-12Rβ-chain and thus unable to elicit Th1 responses showed increased inflammation in the CNS and a more rapid progression to paralysis upon immunization with an encephalitogenic peptide (MOG)67. In this model, increased levels of IL-23mRNA expression were detected compared to control mice with normal IL-12Rβ expression. Antigen stimulated splenocytes of  IL-23-/- mice had increased IL-17 and TNF-α production and less IFN-γ67. In another study with these knockout mice mice, EAE could not be induced and IL-6, IL17 and TNF-α expression was completely absent upon restimulation with the MOG peptide in vitro5. IL-23 blocking antibodies elicit a similar phenotype as the knockout mice5. Blocking IL-23 before immunization prevents induction of EAE and administration of the antibody after immunization ameliorates the disease68. Anti-IL-17 did decrease disease severity, but not as profound as anti-IL-23, probably due to effects of TNF-α and IFN-γ produced by Th17 cells68, whereas in IL-23-/- and IL-21-/- mice no Th17 cells develop at all.
Human Th17 cells were shown to kill CNS derived foetal neuronal cells in vitro50. They were shown to be more capable of crossing a layer of blood-brain-barrier epithelial cells and allow influx of other CD4+ T cells, serum albumin and neutrophils50. However, in the EAE model no difference in infiltration of immune cells was seen in IL-23 deficient mice, questioning the contribution of decreased blood-brain-barrier functioning in the EAE model system5. The role of IL-17 and IL-22 on human brain epithelial cells, astrocytes and microglial cells could be of importance as well, but remain to be characterized30. 
Taken together, Th17 cells appear to be the main contributors to pathology in MS and are a promising target for drug development.

Dermal inflammation, psoriasis and acanthosis
Even before Th17 cells were recognized to be a separate Th subset, IL-23 was implicated to be involved in psoriasis69. In this chronic inflammatory skin disease leukocyte infiltration of dermis and epidermis, dilation and growth of blood vessels and hyperplasia of the skin (acanthosis) is seen. In these skin lesions, IL-23 mRNA was shown to be increased more than 10 and 20-fold respectively for its two subunits69. (The p40 subunit is shared with IL-12, which’s levels were not elevated, explaining the discrepancy between the two subunits.) Subsequently, injection of IL-23 or IL-6 in mice ear can induce dermal inflammation and acanthosis33. The infiltrating CD4+ T cells showed a Th17 phenotype, expressing IL-17 and IL-22. Mice lacking IL-22 showed dramatically decreased pathology and in a mouse model for psoriasis, IL-22 blocking antibodies ameliorated the disease70. In humans similar findings are described. Firstly, IL-22 expression is shown to be increased in psoriatic skin47. Secondly, IL-22 induces psoriatic symptoms in cultured human epidermis49 and thirdly, IL-22 levels in plasma correlate with disease severity71. Taken together there is strong evidence that Th17 produced IL-23 induces IL-22 expression, which in turn leads to dermal inflammation and psoriasis. 
Therefore, blocking antibodies for these two cytokines are promising as a new treatment for psoriasis and indeed, a phase II clinical trial with antibodies for the IL-12/IL-23 p40 subunit are shown to dramatically decrease disease severity72.

Primary Sjögrens Syndrome
Sjögrens Syndrome is an autoimmune disease affecting exocrine glands, resulting in destruction of salivary and lachrymal glands. The disorder is called pSS when encountered alone and secondary Sjögrens Syndrome when it is combined with another autoimmune disorder. PSS is described to be Th1 dependent, but expression of IL-17 and IL-23 is reported to be upregulated in cells infiltrating the glands (mainly CD4+ T cells) and glandular epithelial cells from pSS patients63, 73. As well, IL-17 producing cells are described to infiltrate the glands of pSS. Taken together, this suggests that Th17 are involved in pSS as well, but very little is known about the contribution of Th17 cells in pSS and will therefore have to be investigated further 63.

RA and its experimental models
The disorder in which Th17 involvement is studied most intensively, is RA. Chronic inflammation of synovial tissue associated with bone and cartilage damage hallmark this disease. As in most diseases described above, RA was initially thought to be Th1 mediated, as well as its prototypical mouse model, collagen-induced arthritis (CIA)30. These studies showed IFN-γ to be expressed in serum and synovial fluid of RA patients and administration of IFN-γ to worsen CIA severity 74, 75. In cotrast, IFN-γ and IFN-γ receptor deficient mice are shown to develop more severe CIA76, 77 and IFN-γ deficiency makes mouse strains that are normally resistant to CIA susceptible78. These disrepancies clearly demonstrate that IFN-γ can either be protective protective or attributing to in CIA 75. Indeed, when using IFN-γ blocking antibodies, the moment of administration determines whether the antibodies are protective or not30. As well, IL-12-/- mice are protected from CIA79. Since these mice are driven towards a Th1 profile but protected from CIA, it further supports the hypothesis that Th1 cell are not the subtype responsible for pathology in this experimental model.
For IL-17, its role in RA is demonstrated as well. IL-17-/- mice develop less arthritis and blocking antibodies reduce joint inflammation, bone erosion and cartilage destruction in CIA80, 81. As well, two other mouse models for RA in which the disease develops spontaneously require IL-17 for disease development, namely the IL-1Ra deficient and SKG mice82, 83. In humans, IL-17 and TNF-α mRNA expression in the synovium are shown to correlate with joint damage progression, while IFN-γ mRNA expression was predictive for protection from joint damage progression84, which clearly illustrates the importance of IL-17 in the pathogenesis of RA. As described above, IL-17 induces expression of CXC-ligands and G-CSF, leading to attraction of neutrophils, CD4+ T cells, monocytes and T cells, all of which populate the inflamed joint30. 
Two other cytokines overexpressed in RA are TNF-α and IL-1β. Both cytokines promote Th17 generation 8 and can synergize with IL-17 in inducing inflammation and joint damage 30. The other way around, IL-17 can induce expression of these cytokines30. Moreover, TNF blocking agents are widely used for treating RA patients with significant efficacy. However, by blocking IL-1β or IL-17 as well, efficacy could be improved and treat patients nonresponsive to TNF blockers. 
IL-23 is already implicated in other diseases and might play a role in RA as well. It is upregulated in serum and synovial fluid of RA patients 85 and STAT4, one of its downstream signalling molecules is identified as a susceptibility gene for RA 86. Further supporting the role of IL-23, mice deficient of the cytokine or STAT4 develop less severe arthritis 79, 87.
Also upregulated in serum and synovial fluid are IL-21 and IL-2288, 89. For IL-22, its effects on the joints of RA patients is still unknown30, High expression levels of the IL-21 receptor are found on synovial cells90 and blocking IL-21 with an IL-21R fusion protein decreased disease severity in the CIA model91, implicating a role for this cytokine as well.
The last interleukin implicated in Th17-disfunction, especially in RA, is IL-15. Just like the other cytokines, it is overexpressed in RA patients’ synovial fluid and blood and it can induce IL-17 secretion from PBMCs92. Synovial fibroblasts from RA patients produce IL-15, which induces expression of IL-17 and TNF-α from T cells. In turn, these cytokines stimulate fibroblasts to produce IL-6 and IL-15, creating a positive feedback loop93. Injecting CIA mice with an IL-15 receptor antagonist downregulated expression of Th17 cytokines and ameliorated disease94 and IL-15-/- showed slightly decreased disease incidence and severity as well95. The other way around, IL-15 overexpression in mice induced a higher incidence and severity of CIA95.
The previous sections illustrate that high Th17 cytokine concentrations are found in synovium of RA patients. These cytokines are proposed to be activating T cells without involvement of antigen stimulation as large numbers of T cells are found in the synovium which functionally resemble T cells solely activated by cytokines in vitro. 
Beside these high cytokine levels, RA is characterized by bone destruction in the joints. Since blocking Th17 cytokines has effect on disease severity, Th17 might be involved in bone destruction as well. Indeed, IL-17 was shown to promote proteoglycan and collagen II release (indicative for matrix destruction) for bovine cartilage explants96. In an in vitro study with mice metatarsils, IL-17 alone was unable to induce cartilage destruction. TNF-α however, did induce damage, which was even more profound in combination with IL-1797. In this second study, explants were depleted from osteoclasts, professional bone resorbing cells, indicating that IL-17 and TNF-α might induce proliferation of osteoclasts or induce other mechanisms of bone destruction. In human bone and synovium samples from RA patients, IL-17 induced collagen destruction and prevented new collagen synthesis98, indicating that IL-17 plays a role in human joint destruction as well. A first way to induce bone destruction is by upregulating or activating collagen and proteoglycan degrading proteins. Addition of exogenous IL-17 was shown to increase expression of one of these proteins, matrix metalloproteinase-1 (MMP-1), by 5-fold in isolated synoviocytes isolated from RA patients99. However, the same experiment with cultured whole explants from the synovium did not show any effect of IL-17 on MMP-1 production99. A second way to induce bone destruction is by generation of osteoclasts. Th1 and Th2 cells were shown to be unable to induce osteoclastogenesis in two different experimental systems100. In presence of Th17 cells, though, osteoclasts were efficiently formed. Th17 cells from IL-17-/- mice showed a reduced ability to generate osteoclasts. Addition of IL-17 or IL-23 could only induce osteoclastogenesis in coculture with osteoblasts, cells supporting osteoclastogenesis100. This induction by osteoblasts was shown to be dependent on, receptor activator of nuclear factor kappa B ligand (RANKL) which is well known to induce ostoclastogenesis100, 101. 
Taken together, there is strong evidence supporting the pathological role of Th17 cells in RA and its animal models. However, in another animal model, proteoglycan-induced arthritis is shown to depend on IFN-γ, suggesting that Th1 might be more dominant in RA in some patients, while in others the Th17 subtype plays has a more prominent role102.

Evidence for protection by Th17 cells or cytokines
Though IL-22 is shown to be required for chronic inflammation in psoriasis, it can also be protective in chronic liver inflammation. It can protect hepatocytes from serum starvation-induced apoptosis in vitro in a STAT3 dependent manner and administration of IL-22 prior to injecting proinflammatory molecules reduces the amount of damage in the liver in vivo 103. On the other hand, liver specific STAT-3 deficient or IL-22-/- mice have a reduced ability to recover from liver injury in vivo 104 and IL-22 blocking antibodies exacerbate injuries during acute liver inflammation103. After the discovery of the Th17 subset, IL-17 was tested for protective effects in liver inflammation, but although IL-17RA and IL-17RC are expressed in these cells, the cytokine induced neither protective nor proinflammatory effects 105. Taken together these experiments show a protective role for a Th17 derived cytokine in contrast to many other diseases in which the T cell subtype contributes to pathological symptoms. This decreases the cytokines potential as a drug target, since increased IL-22 levels might induce autoimmune diseases and decreased levels could be dangerous in combination with liver damage.
As stated above, IL-21 is also implicated to have suppressive capabilities58. In a murine T cell mediated contact hypersensitivity (CHS) model, IL-21 abrogated the ability of DCs to stimulate CD8+ T cells in vitro, thus preventing activation and proliferation. In this model, mice are injected with FITC stimulated DCs. After administration of FITC on the skin two weeks later, these mice develop a CHS response. However, stimulating these DCs with IL-21 prior to injection abrogated their ability to induce CHS in vivo as well. Subsequent injection of non-IL21 stimulated, FITC incubated DCs in the same mice could not induce CHS anymore, demonstrating that IL-21 incubated DCs might also induce antigen-specific tolerance. 


IL-7Rα ligand functioning in developing and mature T cells

Th17 cells and other effector T cells show surface expression of IL-7Rα. The receptor is essential in survival and development of cells differentiating to T cells as well as in mature T cells106. Also, the receptor and its ligands play a role in Th subtype differentiation and are implicated in immunopathology. Therefore, the following section will discuss the roles of IL-7Rα and its ligands in healthy individuals and immune disorders.
IL-7 is a cytokine essential in lymphocyte development and survival, and expressed in many tissues by epithelial, stromal and dendritic cells107. Most IL-7 producing cells are not immune cells, while the targets of the cytokine are106, 108. The cytokine is a 177 amino acid glycosilated peptide which has a 81% homology between human and mice109. IL-7 is tissue-derived, since it is primarily produced in epithelia, but expression is also found in the liver and dendritic cells (DCs)109. Its production does not seem to be tightly regulated under normal circumstances, though overexpression of the cytokine is implied to play a role in autoimmunity, as will be discussed below. In a non-inflamed environment, TGF-β is shown to influence IL-7; it decreases mRNA levels and protein secretion from human stromal cells and inhibits IL-7 induced proliferation of human B-cell precursors110. In turn, IL-7 can down-regulate TGF-β, pointing to a balance between production of these cytokines and a possible immunoregulatory role109, 111. The lack of regulation at the level of expression and secretion suggests that IL-7 signalling is regulated at another level, probably by regulating expression of its receptor, which will be discussed below.
Similar to IL-7, TSLP is not produced by most immune cells. Mast cells are the only hematopoietic cells expressing the cytokine112. Non-heamatopoietic cells expressing TSLP are lung fibroblasts, smooth muscle cells, skin keratinocytes and bronchial epithelial cells113. Little is known about the regulation of TSLP expression, but mast cells are shown to upregulate expression upon stimulation by IgE crosslinking113.

IL-7Rα associates with the γc or TSLPR-chain
IL-7 signals through the IL-7 Receptor (IL-7R), a heterodimeric protein consisting of a 440aa IL-7Rα-chain and a common cytokinereceptor γ-chain (γc). This common chain is shared by receptors for IL-2, IL-4, IL-9, IL-15 and IL-21, which compete for the limited amount of available γc109, 114. As well, IL-7Rα can associate with another γc-like chain, called the TSLP receptor (TSLPR)-chain. Heterodimerization of IL-7Rα and TSLPR results in a new receptor specifically binding thymic stromal lymphopoietin (TSLP)115.Therefore, IL-7 and IL-7Rα knockout mice show different phenotypes, as TSLP signalling is abrogated in the receptor knockout as well116. For IL-7 to signal properly, both IL-7Rα and γc are required, but since γc is ubiquitously expressed in lymphocytes, surface expression of IL-7Rα on a lymphocyte indicates that the cell is able to respond to IL-7109. This expression has been seen on immature B and T cells and most mature T cells109, 117, but also on DCs and monocytes118. The TSLPR chain shows an overlap in expression, with protein or mRNA reported on DCs, pre-activated T cells and mast cells 118-120. Moreover, NKT cells are implicated to respond to TSLP as well 121.

IL-7Rα, γc and TSLPR signalling
As stated above, binding of IL-7 to its receptor induces several reactions by the cell, such as proliferation, cell cycling or survival. Upon ligand binding, the two IL-7R chains heterodimerize (Fig. 4)122. Both chains activate an associated Janus kinase (JAK), being JAK-1 and JAK-3 for IL-7Rα and γc, respectively123. Upon activation, these JAKs phosphorylate the IL-7Rα chain, creating docking sites for signal transducers and activators of transcription (STAT)-1, STAT-3 and especially STAT-5124, 125. In turn, the STAT molecules are phosphorylated by the JAKS and dimerize126. The STAT dimers translocate to the nucleus where they modulate the expression of several genes involved in cell survival and proliferation, like the previously mentioned Bcl-2127. As well, STAT-5 is described to function in the cytoplasm by binding scaffold protein Gab2 and activate the PI3K/Akt and Ras/MAPK pathways which are both involved in cell proliferation128. However, these experiments were performed in cell lines and the Ras/MAPK pathway does not appear to be activated in peripheral T cells 129, whereas the contribution of the PI3K/Akt pathway is still a matter of debate126. 





IL-7Rα is crucial in lymphocyte development
The nonredundant role for IL-7 in lymphopoesis is most clearly demonstrated by mice deficient in either IL-7 or IL-7Rα. In these mice, B and T-cell development is severely impaired and γδT cells are completely absent 116. TSLP-/- mice show no changes in lymphocyte development, but a combination of γc and TSLP impairment is more severe than in mice only deficient in γc 116. As well, IL-7-deficient mice show less severe impairment than IL-7Rα -/- mice, suggesting that TSLP can substitute for IL-7 to some extent116. Even further, overexpression of TSLP in IL-7-/- mice can rescue B and T cell development 132, providing more evidence that TSLP can substitute for IL-7.
In humans, no TSLP or IL-7 specific deficiencies have been described, but patients with an IL-7Rα mutation are. This impairment of IL-7Rα leads to T-B+NK+ SCID confirming that IL-7 plays a role in human T-cell development as well133. However, the presence of B-cells in these patients shows that IL-7 is not absolutely required for B-cell lymphopoiesis, but a role for the cytokine in promoting proliferation under normal circumstances is likely.
As stated above, a cells ability to respond to IL-7 is based on IL-7Rα expression and can therefore be easily assessed. During lymphopoiesis, IL-7Rα expression is first seen on the common lymphoid progenitor (CLP) in the bone marrow, which can differentiate into T cells, but preferentially to B-cells107. However, other early lymphocyte progenitors are not expressing IL-7Rα, yet able to efficiently generate T cells107. Altogether, some early progenitors express IL-7Rα, but this is in no way a universal feature, indicating that IL-7 is not absolutely required in the earliest stages of T cell development.
After the first stages of T-cell development, IL-7 is crucial in differentiation through four so-called double-negative (DN) stages, wherein cells express neither CD4 nor CD8 and reside in the thymus. In these stages IL-7 serves as a potent growth factor, implicating a role in proliferation. As well, inhibition of apoptosis was shown to be important as well, since T-cell development in IL-7Rα knockouts can partially be rescued by overexpression of Bcl-2 or deletion of the Bax gene (leading to impaired apoptosis)134, 135. Other experiments show that IL-7 is mainly required to overcome inhibitory signals, since certain chromosomal deletions allow mice to generate T cells in absence of IL-7136.
It is in these stages that VDJ rearrangement of the TCR γ-chain takes place in γδT cells. During this process, IL-7 signalling leads to histone acetylation, making the VDJ locus accessible for rearrangement137.
During the next step of development, the intermediate single positive (SP) stage, IL-7Rα expression is lost. Moreover, forced expression of IL-7Rα in this stage leads to decreased thymic output. This effect may occur due to a higher consumption of IL-7, but forced expression has also shown to inhibit transcription factors required for progression to the next stage107, 138. During this next (double positive) stage, IL-7Rα expression is still repressed. Even further, forced expression of the receptor is shown to be unable to signal into the cell, as an inhibitor (suppressor of cytokine signalling, SOCS-1) is highly expressed at this stage 139. After its double positive stage, the cell regains its IL-7Rα expression while progressing into its final, SP, stage and leaves the thymus as a naive CD4+ Th cell or a CD8+ cell107. Whether the cell differentiates into a CD8+ or a CD4+ cell is also influenced by IL-7Rα, as the receptor is shown to be involved in commitment to the CD8+ lineage 140. TSLP on the other hand, shows preference for CD4+ T cell expansion, indicating a possible difference between stimulation with TSLP of IL-7.

IL-7Rα ligands in peripheral T-cell homeostasis
After leaving the thymus, T cells are still influenced by IL-7. It plays a major role in regulating the amount of T cells in the periphery, as can be seen most strikingly in lymphodepleted hosts. After lymphocytes are depleted, there is no increase in lymphocyte production in the thymus. Instead, the little cells produced or still present in the periphery proliferate at high rate to increase the lymphocyte pool107. This process is called homeostatic peripheral expansion (HPE). During HPE IL-7 levels rise and the T-cell pool grows rapidly. This growth has been shown to be dependent on both IL-7 and TCR signalling141; without IL-7, only cells bearing TCRs with high affinity for antigen can proliferate141. The role of IL-7 is shown to be independent of the method by which lymphopenia is induced107 and is seen in neonatal mice as well142. The role of TSLP in HPE is shown in sublethally irradiated mice only and effects are not as profound as for IL-7116. However, TSLPR knockouts show weakened recovery of lymphocyte numbers, indicating that this cytokine is required for HPE as well.
Besides having effects in lymphodepleted hosts, IL-7 is important under physiologic conditions. Cells that have just left the thymus, recent thymic emigrants (RTEs), express high levels of IL-7Rα and both their survival and proliferation are promoted by IL-7 in vitro143. In vivo, peripheral naive T cells depend on IL-7 for survival and proliferation as well143, 144. Also, memory T cells require IL-7 for survival and the cytokine has been implicated to be involved in commitment of CD8+ cells to the memory phenotype, but this is still a matter of debate143. 


IL-7 concentrations are regulated by consumption
As mentioned above, inactive T cells (naive and memory) require IL-7 to maintain their numbers. When IL-7 levels rise during HPE or after injection of exogenous IL-7, T cells start proliferating at a high rate until a new equilibrium is reached145. The other way around, after administration of IL-7 blocking antibodies, the T-cell pool cannot be maintained146, indicating a role for IL-7 in regulating the size of the inactive T-cell pool. Upon encountering of antigen or activation by other cytokines, T cells downregulate IL-7Rα expression146. These activated cells proliferate, but since they do not express IL-7Rα anymore, they do not consume the cytokine and the pool of inactive cells is maintained107, 143, 146. After antigen is cleared and proinflammatory cytokines are no longer present to provide anti-apoptotic signals, they go into apoptosis unless they express IL-7Rα and form memory T cells143.

IL-7 and TSLP influence antimicrobial defence by influencing Th subtype commitment
As stated above, the immune system requires different Th subsets to clear different pathogens. For efficient clearing of a certain pathogen, the right Th cells have to be activated. In this regulation of Th lineage decision lays another important role for the IL-7Rα ligands. Firstly, IL-7 is shown to induce production of Th1 cytokines in mononuclear cells isolated from synovial fluid of RA patients147. As well, activated T cells preincubated with IL-7 showed an increased production of TNF-α and IFN-γ147. Besides this direct effect of IL-7 on T-cells, the cytokine was also shown to indirectly induce IFN-γ secretion in an IL-12 dependent manner147. As well, IL-7 is also shown to induce IL-17 production from peripheral blood monocytes isolated from pSS patients (Bikker, A et al. In press) and in monocytes isolated from RA patients148.
In contrast, TSLP skews the immune system to a Th2 response. In mice, TSLP was shown to directly induce a Th2 phenotype (IL-4 production) in CD4+ T cells149. In humans, however, TSLP fails to directly induce Th2 proliferation150. This inability to respond to TSLP could be contributed to the observation that TSLPR is not expressed on naive T cells, but only on preactivated cells151. When stimulating these activated cells with TSLP, they show and increased expression of IL-2Rα, thus increasing the sensitivity IL-2 and augmenting proliferation120. Although, TSLP is unable to directly drive naive cells towards a Th2 profile, it can in presence of DCs. DCs stimulated with the cytokine express Th2 cytokines and OX40 ligand150, activate naive T cells and induce differentiation to Th2 cells120. This induction is shown to depend on the expression of OX40L 









The link between IL-7Rα ligands and Th17 cells in immunopathology

IL-7Rα ligand Th subtype commitment in immunopathology
Besides their normal roles in the immune system, IL-7Rα and its ligands are implicated in immune disorders. The following section will discuss these proteins in pathology and integrate their role with that of the Th17 subtype.
A first indication of IL-7Rα being involved in autoimmunity is overexpression of IL-7 in several diseases. Increased expression is seen in inflamed tissue in juvenile idiopathic arthritis152, psoriasis153, ulcerative colitis154, polychondritis (not significant) 155, primary Sjögren’s Syndrome148, sponylarthritis156 and RA157. As well, CD4+ cells in the synovium of RA patients are shown to be hyperresponsive to IL-7157. In vitro, the cytokine upregulates expression of several costimulatory factors, such as CD40, CD69, CD80, CD86 and LFA-1157, 158, implicating it could play a role in activating T cells. IL-7 is shown to induce proliferation of autoreactive T cells and these autoreactive cells are in a more activated state in MS159. Also, the cytokine can induce expression of Th1 cytokines in joints of RA patients147 and IL-17 from PBMCs of pSS patients148. IL-7 promoting IL-17 and Th1 cytokine production suggests that it can induce generation of Th1, Th17 and Th17/Th1 cells. Therefore, it might contribute to pathology in disorders which are associated with these Th subtypes by driving naive T cell differentiation towards these potentially pathological Th subtypes.
For TSLP, overexpression is seen in typical Th2 mediated disorders. In normal skin, histologic staining does not show any TSLP at all. In patients with atopic dermatitis, the cytokine is seen in normal skin neither, but highly expressed in acute and chronic atopic dermatitis lesions113. As well, high levels of TSLP are associated with airway inflammatory disease in both human and mice112, 150. Moreover, TSLPR-/- mice are unable to develop inflammatory allergic responses in the lung 160 and overexpression of TSLP induces both spontaneous airway inflammation and atopic dermatits161, 162. 
In contrast, TSLP is suggested to be protective for inflammatory bowel disease163, which is considered Th1 or Th17 driven62, 163 70% of patients with Crohn disease had no TSLP mRNA expression in d gut epithelial tissue, suggesting that dysregulation of TSLP expression might contribute to pathology or that pathology dysregulates TSLP expression163,




IL-7 promotes expression of other cytokines resulting in positive feedback loops
Besides its potential role in Th subtype commitment, IL-7 is shown to induce several other cytokines involved in immune disorders. Firstly, IL-7 is shown to induce TNF-α production164, a cytokine clearly shown to be an important mediator in RA158. In turn, TNF-α increases IL-7 production by synovial fibroblasts and bone marrow stromal cells, creating a positive feedback loop165, 166(Fig 7). Since generation of Th17 cells is shown to be promoted by TNF-α and these cells coexpress the cytokine together with IL-17, this suggests that IL-7 might contribute to Th17 functioning. A similar positive feedback loop exists for IL-15 and TNF-α, to which IL-7 might contribute by promoting TNF-α expression8, 30, 93.
In autoimmune diseases, Tregs are considered to be protective, preventing disease onset or progression. In vitro, IL-7 and IL-15 are shown to directly impair suppressive capabilities of Tregs 152, 167. As well, IL-7 can interfere with Treg generation, since it can downregulate TGF-β production 168. Disabling Tregs to suppress activated immune cells or to develop at all could be a factor contributing to autoimmune diseases, but not only Tregs depend on TGF-β, Th17 cells require it as well. Even further, TGF-β inhibits IL-7 expression168. Taken together, this would imply that compartments with high IL-7 concentrations prevent Th17 development and that compartments in which Th17 cells do develop IL-7 expression is suppressed. However, both IL-7 and Th-17 cytokines are upregulated in inflamed tissue of several immune diseases and seem to cooperate in inducing inflammation. 
Another Th17 cytokine influenced by IL-7 is IL-21. IL-7 and IL-15 both induce expression of the Th17 cytokine169. These three cytokines are all shown to synergize in the induction of CD8+ T cell activation57, 109, providing more evidence for a relation between IL-7 and Th17 cells. However, IL-7 and IL-21 both require the γc chain for signalling. Therefore, both receptors might compete with each other for γc association and signalling143, but whether this takes place in vivo or influences a cells response to the cytokines is unknown.
Another convergence of Th17 and IL-7 functioning is in the production of MMPs, proteinases contributing to bone destruction in RA170. MMP-1 production by isolated synoviocytes is increased by IL-1799. In turn, IL-7 induced MMP-13 production by human chondrocytes and proteoglycan release from cartilage explants170.







Taken together, there is strong evidence of Th17, as well as IL-7 involvement in autoimmune diseases. All cytokines involved show several overlapping positive feedback loops (Fig 7), inducing more and more production of proinflammatory cytokines. These feedback loops are likely to lay at the basis of all autoimmune diseases. However, differences in patients and diseases might result in different feedback loops, cytokines and Th subsets being involved in each individual case. Therapies aiming to stop these feedback loops by inhibiting one or multiple cytokines seem promising, though. Anti-TNF-α has already been used with great success, but a large group of patients does not respond to treatment. This non-responsiveness could be due to different mechanisms being involved in non-responders compared to good responders. 
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Fig 5. IL-7Rα ligands differentially induce naive T cell differentiation. TSLP stimulated DCs drive T cells to a Th2 phenotype by expression of OX40 ligand and secreting Th2 cytokines. IL-7 can induce IFN-γ, TNF-α and IL-17 secretion in a direct and an indirect manner by inducing IL-12 production from DCs. Secretion of these cytokines points towards differentiation into a Th1, Th17 or possibly to a Th17/Th1 phenotype.



















Fig 7. Differentiation of naive T cells into Th17 cells is promoted by several cytokines. Together, these cytokines form a complicated network in which they stimulate or inhibit each other, with some forming positive feedback loops which might lead to autoimmune diseases. 

Fig 1. Stimulation of naive T cells with a combination of TGF-β and IL-6 or IL-21 induces expression of RORγt and differentiation into Th17 cells. IL-21 promotes proliferation of newly differentiated Th17 cells and is produced by these same cells, forming a positive feedback loop. IL-23, in turn, stabilizes the Th17 phenotype and the cell starts producing all of its characterizing cytokines8.

Fig 6. IL-7Rα ligands drive proliferation towards different Th subsets, which are associated with different diseases. Th cells prevent generation of other Th subtypes, which could prevent or ameliorate diseases associated with these other Th subtypes. Also, Th specific cytokines might directly ameliorate or prevent disease.



18



